Your body.
Your control.
Your freedom.™
PaxosMedical is ending the tyranny of the catheter. We’re building the first patient-activated, on-demand voiding solution for the 20+ million Americans living with Underactive Bladder.
The Problem
The catheter was never the answer.
It was often the only option.
01
Catheterization is a sentence,
not a solution.
Seven times a day. Every day. For life. Clean intermittent self-catheterization carries infection risk, dignity erosion, and a bag of supplies that determines where you go, how long you stay, and what you do. Patients have adapted to a life smaller than it used to be. They shouldn't have had to.
02
There are limited options for Underactive Bladder.
20+ million Americans live with Underactive Bladder — the inability to voluntarily void without catheterization. Current neuromodulation therapies focus on suppressing the bladder, not activating it. The mechanism has been wrong from the start.
03
The market is large, unserved,
and reimbursement-ready.
A $25 billion potential market. Designed to utilize existing PNS CPT codes. ~$38–40k facility reimbursement at 2026 Medicare rates. Urologists already performing similar procedures. The path to market doesn't require a new infrastructure, it requires a new mechanism.
Patients are waiting. Not patiently.
Patients are waiting. Not patiently.
UnderControl™ Therapy
The body was designed to do this.
We give it back the signal.
Water finds dry ground. Neural signals find blocked circuits. In both cases, the mechanism was always there — waiting for the right activation. PaxosMedical isn't engineering a workaround. We're restoring what the body already knows how to do.
Forty years of Duke and Pittsburgh research established that the voiding neural circuit responds to pro-voiding stimulation parameters. Not suppression. Activation. The patent is granted. The preclinical data shows 100% efficacy. First-in-human is the next step.
01
On-demand activation
UnderControl™ is a minimally invasive implant that is designed to restore on-demand bladder voiding — no catheter, no schedule, no bag of supplies. The patient activates it, at the moment they choose, through the body's own neural circuit. Control is not a feature. It is the entire point.
02
Patented, anatomically specific, pro-voiding mechanism
US 12,337,173 B2. Anatomically specific, pro-voiding stimulation parameters developed over 40 years. The only activation-based neuromodulation designed to specifically target the voiding and maintenance neural circuit.
03
Outpatient procedure
Fits existing urologist skill and reimbursement infrastructure.
04
Platform architecture
Designed to expand beyond UAB to neurogenic and non-neurogenic etiologies. A platform, not a product.
PaxosMedical Leadership
An unusually senior bench
for a Seed-stage company.
The PaxosMedical team brings together decades of experience in neuromodulation device development, commercialization, and clinical science from the industry's most consequential companies, and the conviction that meaningful science doesn't have to get slow-walked.
Jeff Erb, MBA
Co-founder, Chief Executive Officer
Medtronic Neuromodulation
Experienced Strategic Leader with ~25 years at Medtronic & various neuromodulation startups
Jon Ruais, MBA
Co-founder, Chief Operations Officer
Nalu Medical, St. Jude Neuromodulation
Experienced Commercial Leader With ~20 years at Nalu Medical & various other medical roles
Matt Fraser, PhD
Co-founder, Chief Scientific Officer
Experienced Research Leader with ~40 years at
Duke University & the University of Pittsburgh
Ben Tranchina
Chief Technology Officer
St. Jude Neuromodulation,
ImCube, NIT
Research and Technology
Jeff Kramer, PhD
Vice President, Therapy Development
Medtronic & Abbott Neuromodulation
Experienced Clinical Scientist and Research/Technology leader with over 30 years experience.
Eric Bosler, MBA
Vice President, Finance
Various Medtech Companies
Experienced Financial Leader with ~35 years at Medtronic & various other financial roles
Orlando Flores
Corporate Counsel
Medtronic, Cerepedics
Experienced Corporate Legal leader with over 30 years experience
John Swoyer
Vice President, Engineering
Experienced Medical Device Technology leader with extensive expertise in implantable neuromodulation and gastric stimulation therapies
Life After UnderControl™
A $25B potential market.
20+ million patients destined for catheters.
One company changing that.
Existing CPT codes. Urologists already performing similar procedures. The path to market doesn't require a new infrastructure, it requires a new mechanism.
Whether you're an investor, clinician, potential team member, or patient advocate — we want to hear from you. The work is urgent. So are we.
Ending the tyranny of the catheter.
Restoring control, on demand.